|  |
| --- |
| **Basic details** |

**1A. Full project title:**

**1B. Project acronym (if applicable):**

**2. Contact details of main applicant (‘project coordinator’)**

*If applicable, please list all co-applicants from one organisation under the same consortium partner in the designated table.*

|  |  |
| --- | --- |
| **Consortium partner 1** | |
| Name of the organisation |  |
| Department |  |
| Name of contact person, title(s) |  |
| Male/female/other |  |
| Position |  |
| Address for correspondence |  |
| Telephone |  |
| E-mail: |  |
| Type of organisation | *Health fund/company (for profit enterprise)/research organisation/non-profit enterprise/other* |
| SME (MKB)   * Type of SME   (for SME definition see Appendix A) | *Yes/No*  *Medium/Small/Micro/NA* |
| Chamber of commerce number or equivalent |  |
| URL of own web page |  |
| (Scientific) excellence and expertise of the main applicant and added value of the main applicant to the quality of the project |  |
| Benefit of this project for the main applicant |  |

|  |  |  |  |
| --- | --- | --- | --- |
| Co-applicants from the same organisation as consortium partner 1 | | | |
| Department | Name of contact person, title(s) | (scientific) excellence and expertise and added value of the co-applicant to the quality of the project | Benefit of this project for the co-applicant |
|  |  |  |  |

**3. List of consortium partners (co-applicants)**

|  |  |
| --- | --- |
| **Consortium partner 2** | |
| Name of the organisation |  |
| Department |  |
| Name of contact person, title(s) |  |
| Address for correspondence |  |
| E-mail: |  |
| Type of organisation | *Health fund/company (for profit enterprise)/research organisation/non-profit enterprise/other* |
| SME (MKB)   * Type of SME   (for SME definition see Appendix A) | *Yes/No*  *Medium/Small/Micro/NA* |
| Chamber of commerce number or equivalent |  |
| URL of own web page |  |
| (Scientific) excellence and expertise of the main applicant and added value of the main applicant to the quality of the project |  |
| Benefit of this project for the main applicant |  |

|  |  |  |  |
| --- | --- | --- | --- |
| Co-applicants from the same organisation as consortium partner 2 | | | |
| Department | Name of contact person, title(s) | (scientific) excellence and expertise and added value of the co-applicant to the quality of the project | Benefit of this project for the co-applicant |
|  |  |  |  |

|  |  |
| --- | --- |
| **Consortium partner 3** | |
| Name of the organisation |  |
| Department |  |
| Name of contact person, title(s) |  |
| Address for correspondence |  |
| E-mail: |  |
| Type of organisation | *Health fund/company (for profit enterprise)/research organisation/non-profit enterprise/other* |
| SME (MKB)   * Type of SME   (for SME definition see Appendix A) | *Yes/No*  *Medium/Small/Micro/NA* |
| Chamber of commerce number or equivalent |  |
| URL of own web page |  |
| (Scientific) excellence and expertise of the main applicant and added value of the main applicant to the quality of the project |  |
| Benefit of this project for the main applicant |  |

|  |  |  |  |
| --- | --- | --- | --- |
| Co-applicants from the same organisation as consortium partner 3 | | | |
| Department | Name of contact person, title(s) | (scientific) excellence and expertise and added value of the co-applicant to the quality of the project | Benefit of this project for the co-applicant |
|  |  |  |  |

Etc.

**4. Contribution to the Dutch knowledge infrastructure and economy**

*If there is no participation of a recognised Dutch research organisation/knowledge institution in the consortium, please explain how the results of this collaborative project will benefit the Dutch knowledge infrastructure and economy. Otherwise answer this question with ‘not applicable’.*

**5. Cooperation**

*Please describe the first contact between consortium partners (how, where and when) and what the next steps have been after this first contact.*

**6. Follow-up**

*Please describe the envisioned follow-up of this project (research cooperation and/or investments in the Netherlands)*.

**7. Consortium agreement and IP**

*Please describe the main aspects of the consortium agreement and the anticipated plan regarding intellectual property (IP) generated by the project.*

**8. Start date (dd-mm-yyyy):**

**9. End date (dd-mm-yyyy):**

**10. Duration of the project (max. 18 months):**

|  |
| --- |
| **Project content** |

**11A.** **Summary (max. 300 words)**

*Please describe the background, objective, design, and anticipated social and economic impact.*

**11B. Public summary in Dutch (max. 300 words, in lay language)**

*Please describe the background, objective, design, and anticipated social and economic impact.*

**11C. Keywords (max. 5)**

**12. Research category (see Appendix B)**

1. Please indicate per work package the applicable type(s) of research (more than one option possible).

|  |  |  |
| --- | --- | --- |
| **Types of research** | **yes/no** | **WP** |
| 1. Fundamental research |  |  |
| 1. Industrial research |  |  |
| 1. Experimental development |  |  |

1. Please give an explanation of the chosen research type(s). Make use of the phrasing that has been used to define the three types of research (see Appendix B).

**13. Project description**

*Please address items a to d (max. 3500 words) and include relevant literature references. Insert citations in the text and list the references under point 14 in numerical sequence in the order in which they are first mentioned in the text.*

1. Describe the research topic/background, objectives and hypothesis, and the operationalisation of the concept(s) tested.
2. Outline the work plan per work package (if more than one) in a table or scheme, including: aim, time schedule, milestones and deliverables. Indicate the role and responsibilities of the applicants in the activities.
3. Describe the coherence between the work packages (if more than one).
4. When will the project be considered successful and which criteria will be used to validate this? Describe the overall outcome of each WP that defines the criterium for success with go/no-go criteria. The mere listing of the milestones and deliverables is not sufficient.

**14. Please provide a concise list of references**

*List all authors when there are six or less; when there are seven or more, list the first three, then 'et al'. Avoid using the words 'in press' in references if possible.*

**15. Importance of the project**

1. Please describe how does the project fits within the [Knowledge and Innovation Agenda 2020-2023](https://www.health-holland.com/sites/default/files/downloads/kennis-en-innovatieagenda-2020-2023-gezondheid-en-zorg.pdf) and the general policy theme that is depicted in it (max. 300 words).
2. Please indicate below how the project contributes to one or more of the missions of the Top Sector LSH (max. 300 words):

* Central Mission:

By 2040, all Dutch citizens will live at least five years longer in good health, while the health inequalities between the lowest and highest socio-economic groups will have decreased by 30%.

* Mission I:

By 2040, the burden of disease resulting from an unhealthy lifestyle and living environment will have decreased by 30%.

* Mission II:

By 2030, the extent of care provided to people within their own living environment (rather than in health-care institutions) will be 50% more than today or such care will be provided 50% more frequently than at present.

* Mission III:

By 2030, the proportion of people with a chronic disease or lifelong disability who can play an active role in society according to their wishes and capabilities will have increased by 25%.

* Mission IV:

By 2030, quality of life for people with dementia will have improved by 25%.

**16. Applicable categories**

1. *Please indicate below which roadmap(s) (see Appendix C) is/are most applicable to the project (max. 2 roadmaps).*

|  |  |
| --- | --- |
| **LSH Roadmaps** | **yes/no** |
| 1. Molecular diagnostics |  |
| 1. Imaging & image-guided therapies |  |
| 1. Homecare & self-management |  |
| 1. Regenerative medicine |  |
| 1. Pharmacotherapy |  |
| 1. One health |  |
| 1. Specialised nutrition, health & disease |  |
| 1. Health technology assessment, individual functioning & quality of life |  |
| 1. Enabling technologies & infrastructure |  |
| 1. Global health, emerging diseases in emerging markets |  |

1. Indicate on which of the seven LSH-related Dutch National Research Agenda routes[[1]](#footnote-2) the project applies to (max. 2 routes).

|  |  |
| --- | --- |
| **LSH-related Dutch National Research Agenda routes** | **yes/no** |
| 1. Healthcare research, sickness prevention and treatment |  |
| 1. Personalised medicine: the individual at the centre |  |
| 1. Regenerative medicine: a game-changer moving to broad areas of application |  |
| 1. Creating value through responsible access to big data and its use |  |
| 1. NeuroLabNL: the ultimate living lab for brain, cognition and behavioural research |  |
| 1. Sport and exercise |  |
| 1. Quality of the environment: game-changer ‘Exposome’ |  |

1. Indicate on which of the Key Enabling Technologies[[2]](#footnote-3) the project applies to.

|  |  |
| --- | --- |
| **Key Enabling Technologies** | **yes/no** |
| 1. Advanced materials |  |
| 1. Chemical technologies |  |
| 1. Digital technologies |  |
| 1. Engineering and fabrication technologies |  |
| 1. Life science technologies |  |
| 1. Quantum technologies |  |
| 1. Nanotechnologies |  |
| 1. Photonics and light technologies |  |
| 1. Not applicable |  |

1. Describe why these Key Enabling Technologies are relevant for the project, and thus how the project helps in the application and/or development of these technologies
2. Indicate which of the Key Enabling Methodologies[[3]](#footnote-4) the project applies to

|  |  |
| --- | --- |
| **Key Enabling Methodologies** | **yes/no** |
| 1. Vision and imagination |  |
| 1. Participation and co-creation |  |
| 1. Behaviour and empowerment |  |
| 1. Experimental environments |  |
| 1. Value creation and upscaling |  |
| 1. Institutional change |  |
| 1. System change |  |
| 1. Monitoring and effect measurement |  |
| 1. Not applicable |  |

1. Describe why these Key Enabling Methodologies are relevant for the project by addressing:
   1. How they are embedded in the project’s approach
   2. How expertise on these methodologies is employed within the project (via which consortium partner or third party)
2. Describe if the project aims at researching or developing methodologies, and describe the aims of this part of the project
3. Describe possible collaborations with other public-private partnerships or which of these public-private partnerships are relevant for a future collaboration (see the overview on the Health˜Holland website[[4]](#footnote-5))

|  |
| --- |
| **Prospects** |

**17. Originality/innovativeness**

*Please describe the originality of innovativeness of the project. What is new and unique? What are the novel clinical applications?*

**18. Project outcome and follow-up**

1. Describe the expected societal impact of the project.
2. Describe the expected economic (also for the companies) impact of the project. Please also include a cost-effectiveness analysis or a value-based reasoning to describe the economic impact. How does the project fit the strategic mission(s) of the parties involved?
3. Indicate what the effect on the Dutch economy will be and give an analysis of your position in your competitive environment.
4. Indicate the current and expected Technology Readiness Level (TRL; see Appendix D) of the project (level of development/readiness to go to the market), and why this is applicable for the project.
5. What and who will be needed to bring the innovation to the market/clinic (TRL 9)?
6. Describe the planned activities by each consortium partner in order to promote the dissemination and implementation (including potential exploitation) of the results. This should not be limited to scientific dissemination. Please also include a justification for the chosen approach for each partner.

**19. Data management**

*The data should comply with the FAIR principles (Findable, Accessible, Interoperable, and Reusable;* <https://www.dtls.nl/fair-data/fair-data/>*).*

1. Could the research question(s) be answered with existing data and a therefore suitable research methodology? If not, or only partially, please explain the added value of the new data to existing datasets.
2. Will data be collected or generated that are suitable for reuse? If yes, then answer questions c to e. If not, then explain why the project will not result in reusable data or in data that cannot be stored or data that for other reasons are not relevant for reuse.
3. Where will the data be stored during the project?
4. After the project has been completed, how will the data be stored for the long-term and made available for the use by third parties? To whom will the data be accessible?
5. Which facilities (ICT, (secure) archive, refrigerators or legal expertise) do you expect will be needed for the storage of data during the project and after the project? Are these available? ICT facilities for data storage are considered to be resources such as data storage capacity, bandwidth for data transport and calculating power for data processing.

**20. Patient/end user participation**

*Please describe if and how citizens in their role as patients, end users, clients, and/or loved ones are involved in the design, execution and dissemination/implementation of the current and future projects.*

1. *Are patients or end users involved in the design, execution or results dissemination/implementation of this project? If yes, how? If no, why not?*
2. *How does the consortium envision involving patients/end users in future PPP projects arising from the current kickstarter project?*

**21. Reducing health disparities**

*Please describe how the consortium aims to reduce health disparities in the current project or future PPP projects arising from the current kickstarter project. Specifically, how does/will the project include/reach people with low socio-economic status.*

**22.Inclusivity: Relevant differences within target groups concerned**

*Inclusivity entails paying attention to diversity and differentiation of the target groups concerned, including characteristics as sex, age, socio-economic status (SES), level of education, migration, cultural background, and sexual orientation, to the extent these are relevant for the theme of the current kickstarter project or subsequent PPP projects.*

* 1. Please describe to what extent the (health) problem affects men, women and/or other relevant subgroups.
  2. Please describe and substantiate how the project, or future project, takes into account relevant differences between people (e.g. according to sex and/or gender) in the design, execution, analyses conclusions and publication of your research. If there are no relevant differences, substantiate this.

**23. Risks of the project**

*Are there any risks regarding the execution of the project? List the risks for each WP, the risk mitigation strategy already incorporated in the strategy or the proposed strategy adaptations once risks are encountered.*

|  |
| --- |
| **Human subjects, laboratory animals, biological hazards** |

**24. Will the project involve experiments with patient material?**

|  |  |
| --- | --- |
|  | **Answer** |
| 1. Use of healthy volunteers? | yes/no |
| 1. Use of patients? | yes/no |
| 1. Number of healthy volunteers |  |
| 1. Number of patients |  |
| 1. Is ethical approval from a commission needed regarding experimental subjects? | yes/no/NA |
| 1. If ‘d’ is answered with ‘yes’: Do you already have ethical approval from a commission to perform the study? | yes/no/requested/NA |

**25. Will the project involve experiments with animals?**

|  |  |
| --- | --- |
|  | **Answer** |
| 1. Use of animals? | yes/no |
| 1. What kind of animals are used? |  |
| 1. Number of animals needed for the total project |  |
| 1. Nature of intervention |  |
| 1. Is ethical approval from a commission needed regarding experimental subjects? | yes/no/NA |
| 1. If ‘e’ is answered with ‘yes’: do you already have ethical approval from a commission to perform the study? | yes/no/requested/NA |

**26. Justification for the requirement of experimental animals**

1. Indicate if alternative methods (besides experimental animals) have been considered? Have experts been consulted and has a systematic review been performed?
2. What are the reasons that this project cannot be performed without experimental animals (replacement)?
3. What are the reasons that this project cannot be performed with fewer animals (reduction) or with less distress and discomfort for the animals (refinement)?
4. What are the reasons that this project cannot be performed with a lower species of animals?

**27. Will the project involve biological risks?**

|  |  |
| --- | --- |
|  | **Answer** |
| 1. Use of recombinant DNA? | yes/no |
| 1. If ‘a’ is answered with ‘yes’: provide class of recombinant DNA |  |
| 1. Use of radiation (wave and/or particle)? | yes/no |
| 1. Use of radioactive isotopes? | yes/no |
| 1. Use of pathogenic micro-organisms? | yes/no |
| 1. Are required grants, permits and facilities available? | yes/no/NA |

|  |
| --- |
| **Budget** |

**28. Budget**

*Please specify the project’s budget in the* [*TKI-LSH budget form*](https://www.health-holland.com/sites/default/files/downloads/2021-tki-lsh-match-budget-form.xlsx)*. Use a separate line per consortium partner for their contribution. Do not forget to add the numbers in the ‘total’ column and rows.*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Contribution** | **cash** | **2022** | **2023** | **2024** | **Total** |
| **Research organisation** | In cash |  |  |  |  |
| In kind |  |  |  |  |
| **Company** | In cash |  |  |  |  |
| In kind |  |  |  |  |
| **Other partners** | In cash |  |  |  |  |
| In kind |  |  |  |  |
| **PPP Allowance** | In cash |  |  |  |  |
| **Total funding (incl. PPP Allowance)** | In cash |  |  |  |  |
| In kind |  |  |  |  |
| Total |  |  |  |  |
| **Total project costs** | **Total** |  |  |  |  |

**29. Deployment of PPP Allowance**

*Please indicate for each consortium partner 1) the total costs (incl. in kind contribution); 2) the amount of PPP Allowance that will be used; and 3) the activities that will be financed through the PPP Allowance.*

*Note: each consortium partner must incur payroll costs (in kind) as part of the collaboration.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Partner** | **Total Costs** | **PPP Allowance** | **Activities** |
| **Consortium Partner 1** |  |  |  |
| **Consortium Partner 2** |  |  |  |
| **Consortium Partner 3** |  |  |  |
| **Etc.** |  |  |  |

**30. Budget specification**

*Please provide a justification/specification of the budget per work package or deliverable. Only referring to the budget form is not sufficient.*

**31. Have the consortium partners requested/received any additional grants for this project? Yes/No**

*If yes, please specify grant supplier(s), grant name(s), total amount requested/received per grant (in €) and status (applied/granted) in the TKI-LSH budget form.*

|  |
| --- |
| **Evaluation of health and care innovations** |

**32. Innovation guidance**

*Before answering the questions below, please read section 2.2 of the HHINT Kickstarter 2022.*

|  |  |
| --- | --- |
|  | **Answer** |
| 1. Do the consortium partners intend to apply for CE marking for the health innovation during the project period or within two years after the project period? | yes/no |
| 1. Did the consortium partners contact HI-NL 3 weeks prior to submission of the PPP Allowance application? | yes/no/NA |
| 1. Does HI-NL believe that an innovation guide is recommendable for this project?   *If ‘c’ is answered with ‘yes’: the consortium is eligible to enter an amount of 24,200 euros in the budget form under the heading 'costs due to third parties'.* | yes/no/NA |

|  |
| --- |
| **Statement by project coordinator** |

When submitting your application, please do not forget to upload the required budget form file (Excel), letter(s) of commitment, (concept) consortium agreement.

Please tick the boxes where applicable:

By submitting this form, I declare that I have completed this form truthfully and I declare that I have informed the correct official(s) of my employing organisation of this submission.

I hereby declare that the obligatory letter(s) of commitment of the other consortium partner(s) has/have been uploaded separately.

I hereby declare that the application is checked according to **Appendix G**.

Name:

Place:

Date:

Please note: Information provided in relation to this application will be treated confidentially by Health~Holland. Health~Holland has to inform the Netherlands Enterprise Agency (RVO.nl) on the participants of the project and the in cash and in kind contribution of private partners, in order to claim the requested PPP Allowance. RVO.nl will also treat this information confidentially. Upon granting, the project coordinator will receive a request to provide a summary of the project and other basic project details (see Appendix E) that will be published on the Health~Holland website and for other communication purposes. Other content of the project will not be communicated beyond Health~Holland.

Main applicants must submit this TKI-LSH HHINT Kickstarter PPP Allowance application form by e-mail to [tki@health-holland.com](mailto:tki@health-holland.com). For any questions regarding submission, please send an e-mail to [tki@health-holland.com](mailto:tki@health-holland.com).

Attachments to be uploaded:

* TKI-LSH budget form.
* Letters of commitment of **all** parties involved, each stating the parties’ in cash & in kind (separately) contribution to the project. Only the main applicant does not need to upload a letter of commitment. See Appendix F for a template of a letter of commitment.
* Signed copy of the consortium agreement and IP settlements agreed upon in this project. If a signed consortium agreement is not yet available, a concept agreement must be submitted. The signed consortium agreement may be handed in within 16 weeks after submission.

**Appendix A: European Commission Recommendation 2003/361/EC regarding SME definition**

1. **Micro-enterprises** are defined as enterpris­es that employ fewer than 10 persons and whose annual turnover or annual balance sheet total does not exceed EUR 2 million.
2. **Small enterprises** are defined as enterpris­es that employ fewer than 50 persons and whose annual turnover or annual balance sheet total does not exceed EUR 10 million.
4. **Medium-sized enterprises** are defined as enterprises that employ fewer than 250 per­sons and either have an annual turnover that does not exceed EUR 50 million, or an annual balance sheet not exceeding EUR 43 million.

For more details ‘The revised User Guide to the SME definition’ can be downloaded [here](https://ec.europa.eu/docsroom/documents/42921).

**Appendix B: Definitions of the three types of research[[5]](#footnote-6)**

**Fundamental research** means experimental or theoretical work undertaken

primarily to acquire new knowledge of the underlying foundations of phenomena

and observable facts, without any direct commercial application or use in view.

**Industrial research** means the planned research or critical investigation aimed at

the acquisition of new knowledge and skills for developing new products,

processes or services or for bringing about a significant improvement in existing

products, processes or services. It comprises the creation of components parts of

complex systems, and may include the construction of prototypes in a laboratory

environment or in an environment with simulated interfaces to existing systems as

well as of pilot lines, when necessary for the industrial research and notably for

generic technology validation.

**Experimental development** means acquiring, combining, shaping and using

existing scientific, technological, business and other relevant knowledge and skills

with the aim of developing new or improved products, processes or services. This

may also include, for example, activities aiming at the conceptual definition,

planning and documentation of new products, processes or services. Experimental

development may comprise prototyping, demonstrating, piloting, testing and

validation of new or improved products, processes or services in environments

representative of real life operating conditions where the primary objective is to

make further technical improvements on products, processes or services that are

not substantially set. This may include the development of a commercially usable

prototype or pilot which is necessarily the final commercial product and which is

too expensive to produce for it to be used only for demonstration and validation

purposes. Experimental development does not include routine or periodic changes

made to existing products, production lines, manufacturing processes, services

and other operations in progress, even if those changes may represent

improvements.

**Appendix C: Definitions of the ten roadmaps**

The roadmaps are designed to address priorities in health outcomes (age-related, chronic, acute, infectious, orphan and neglected diseases) and along the healthcare chain (from prevention through diagnosis to cure and care). The roadmaps represent the areas in which public and private parties are committed to co-innovate and ask the government to co-invest. Companies, research institutes, practitioners, patient organizations, health foundations, health insurers, regulators, and many others have contributed and endorsed these roadmaps. Seven roadmaps (1 through 7) are product oriented. They are supported by two that deliver health technology assessment (8) and enabling technologies & infrastructure (9). The latter also links to other Top Sectors with a strong life sciences component, such as Agro-food, Horticulture and Chemistry. A final roadmap (10) is centred around diseases that cause a high burden mainly in the developing world, but for which the developed world can make strides in solving.

1. **Molecular diagnostics**: Development of candidate biomarkers into validated molecular diagnostics for clinical use
2. **Imaging & image-guided therapies**: Development of imaging applications for more accurate and less invasive diagnosis and treatment
3. **Homecare & self-management**: Development, assessment and implementation of technologies, infrastructure and services that promote clients’ abilities to live independently and manage their own care, adequately supported by healthcare professionals
4. **Regenerative medicine**: Development of curative therapies for diseases caused by tissue damage and ensuing organ dysfunction, through repair or renewed growth of the original tissue or replacement by a synthetic or natural substitute
5. **Pharmacotherapy**: Discovery, development and stratified use of new, safe and (cost-)effective medicines in order to cure or prevent progression along the healthcare chain
6. **One health**: Development of solutions like vaccines, optimized antimicrobial use and early warning systems that improve health status of humans and animals by coupling the know-how and infrastructure available in the human and veterinary/agricultural domains
7. **Specialized nutrition, health & disease**: Researching specialized nutrition for nutritional intervention as part of integrated health solutions in terms of prevention, cure and care of chronic, acute and rare diseases
8. **Health technology assessment, individual functioning & quality of life**: Development of methods and knowledge for health technology assessments in which the impact of health innovations on quality of life, cost-containment and productivity is assessed
9. **Enabling technologies & infrastructure**: Development and offering of expertise and infrastructure in cutting-edge molecular life science technologies (e.g. next generation sequencing, proteomics and bioinformatics), in biobanks and in ultramodern research facilities, all readily accessible to industry and academia, and with existing, strong links to other Top Sectors (Agro-food, Horticulture, Chemistry, Biobased Economy and High Tech Systems and Materials)
10. **Global health, emerging diseases in emerging markets**: Development and delivery of solutions to diseases associated with poverty, which affect more than 2 billion people in the developing world

**Appendix D: Technology Readiness Levels**

|  |  |  |
| --- | --- | --- |
| **TRL** | **Definition** | **Indication type of research\*** |
| TRL 1 | Basic principles observed | Fundamental research |
| TRL 2 | Technology concept formulated | Fundamental research |
| TRL 3 | Experimental proof of concept | Fundamental research |
| TRL 4 | Technology validated in lab | Fundamental/industrial research |
| TRL 5 | Technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies) | Industrial research |
| TRL 6 | Technology demonstrated in relevant environment (industrially relevant environment in the case of key enabling technologies) | Industrial research |
| TRL 7 | System prototype demonstration in operational environment | Industrial research/experimental development |
| TRL 8 | System complete and qualified | Beyond the scope of the PPP Allowance Regulation |
| TRL 9 | Actual system proven in operational environment (competitive manufacturing in the case of key enabling technologies; or in space) | Beyond the scope of the PPP Allowance Regulation |

\*The TRL is an indication of the type of research but the definition of type of research (Appendix B) prevails.

**Appendix E: Project page content for Health~Holland website**

**Health~Holland Project Page**

|  |
| --- |
|  |

**An overview of all public private projects and partnerships supported by the Top Sector Life Sciences & Health**

**The Top Sector Life Sciences & Health (LSH) wants to illustrate all its currently accepted and ongoing public private projects and partnerships to our international audience throughout the world. Therefore, the Health~Holland website will be complemented by the new Health~Holland project page. This page will provide an overview of all the projects and partnerships hosted in the Top Sector LSH from the start of the top sector approach. To successfully launch our new project and partnership webpage, we ask you to provide us with a correct, clear, and legible content on your public private partnership’s project (all in British English).**

**Project page content**

*Health~Holland wants to collect content on your public private partnership’s project. Can you provide us with the following aspects on your partnership/project:*

1. **LSH project number**

LSHM …….

1. **Clear popular title**

This title (max. 10 words) appears above the project. No use of abbreviations.

1. **Clear scientific title**

No use of abbreviations and the title must be understandable for the lay public. In addition, the project acronym can be mentioned.

1. **One liner**

The one liner (max. 15 words) includes a short summary of your project, acts as a trigger to read more or describes the relevance of the project.

1. **Short summary of the project**

A short summary of two sentences (max. 50 words) that includes a brief explanation of the project. This summary will be visible on the project page and helps the reader to decide whether to continue reading about the project. The text has to be both informative and excitatory to continue reading. Please do not use jargon or abbreviations that the lay public may not understand.

1. **Public summary**

The public summary consists of 250 to max. 300 words. The summary is intended for a broad audience with a secondary education language level. In short, the public summary describes the who, what, where, when, why and how of the project. Focus on the core message of the project instead of elaborating on explanations and background information.   
  
Health~Holland would like you to follow these guidelines:

* First paragraph: short summary of the whole project (see point 4) with a highlight on the (newly) established public private partnership.
* Second paragraph: introduction on the societal/economic impact and relevance of the health/disease/vital functioning/etc. and why innovation is necessary. Make use of numbers, statistics, or rankings to illustrate the relevance of the project to the lay public.
* Third paragraph: explanation of the project’s approach and conceptualisation, and how this innovative solution will contribute to the previously described societal challenge(s).
* Fourth paragraph: description of deliverables and, if the project is finished, an illustration of the (end)results.

1. **Keywords**

Define a maximum of five clear keywords.

1. **Consortium partners**

Indicate all partners that contribute and send us the original logos of their organisation/company.

1. **Start date of the project**
2. **End date (intended) of the project**
3. **Project duration**
4. **Image (free of copyright)**

The image will be used to illustrate the project, this can include a picture of the laboratory, consortium partners, target audience, product, innovation, building, university, or ambience of the project. It is important that the image is free of copyright so Health~Holland is able to use it in their communication channels.

1. **Link**

If possible a link to a webpage with more information.

**Project page filters**

*Health~Holland makes use of several filters to facilitate the search of projects. Can you select filters that address your public private partnership’s project:*

1. **Objective:** prevention, cure or care *(select one)*
2. **Kind of research:** fundamental, industrial or experimental
3. **Missions of the Top Sector LSH:** 
   1. Central Mission: By 2040, all Dutch citizens will live at least five years longer in good health, while the health inequalities between the lowest and highest socio-economic groups will have decreased by 30%.
   2. Mission I: By 2040, the burden of disease resulting from an unhealthy lifestyle and living environment will have decreased by 30%.
   3. Mission II: By 2030, the extent of care provided to people within their own living environment (rather than in health-care institutions) will be 50% more than today or such care will be provided 50% more frequently than at present.
   4. Mission III: By 2030, the proportion of people with a chronic disease or lifelong disability who can play an active role in society according to their wishes and capabilities will have increased by 25%.
   5. Mission IV: By 2030, quality of life for people with dementia will have improved by 25%.
4. **Major** [**TKI-LSH roadmap**](http://www.health-holland.com/public/downloads/tki-2016/tki-lsh-match-application-appendix-a-roadmaps.pdf) **of project:** *(select one)*
   1. molecular diagnostics
   2. imaging & image-guided therapies
   3. homecare & self-management
   4. regenerative medicine
   5. pharmacotherapy
   6. one health
   7. specialized nutrition, health & disease
   8. health technology assessment & quality of life
   9. enabling technologies & infrastructure
   10. global health, emerging diseases in emerging markets
5. **Minor** [**TKI-LSH roadmap**](http://www.health-holland.com/public/downloads/tki-2016/tki-lsh-match-application-appendix-a-roadmaps.pdf) **of project:** *(select one)*
   1. molecular diagnostics
   2. imaging & image-guided therapies
   3. homecare & self-management
   4. regenerative medicine
   5. pharmacotherapy
   6. one health
   7. specialized nutrition, health & disease
   8. health technology assessment & quality of life
   9. enabling technologies & infrastructure
   10. global health, emerging diseases in emerging markets
6. **Key Enabling Technologies main category of project:** *(select one)*
   1. Advanced materials
   2. Chemical technologies
   3. Digital technologies
   4. Engineering and fabrication technologies
   5. Life science technologies
   6. Quantum technologies
   7. Nanotechnologies
   8. Photonics and light technologies
   9. Not applicable
7. **Key Enabling Technologies subcategory**

See Annex 1 for all subcategories. Indicate the Key Enabling Technologies subcategory that applies to the project. *(Select one)*

1. **Operating in:** bio(pharma), medical technology or healthcare *(select one)*
2. **Technology readiness level (TRL) of project:** select the current and predicted TRL (see attachment A)

Current TRL: -1- -2- -3- -4- -5- -6- -7- -8- -9-

Predicted TRL: -1- -2- -3- -4- -5- -6- -7- -8- -9-

**Comments**

If you have any comments or questions, please note here.

**Editorial rights**

Health~Holland will perform a check on the submitted text prior to publication. If we have any questions regarding the provided content, we will contact you before we publish the content of the project. For more information, please contact Irene Faas ([faas@health-holland.com](mailto:faas@health-holland.com)).

**Annex 1: Key Enabling Technologies subcategories:**

* 1. Advanced materials
     1. Bio (related materials and soft material
     2. Composite and ceramics
     3. Designer and meta materials
     4. Energy conversion
     5. Optical/electronic/magnetic materials (incl 2D and graphene)
     6. Smart/self-healing/self-organising materials
     7. Structural materials
     8. Thin films and coatings
  2. Chemical technologies
     1. (Bio)Process technology including process intensification
     2. Analytic technologies
     3. Catalysis
     4. Electrification/ Hydrogen technology/ power to gas
     5. Microreactors
     6. Separation technologies
  3. Digital technologies
     1. Artificial intelligence (incl. machine learning and deep learning)
     2. Big data and data analytic
     3. Block chain
     4. Encryption technologies/ digital security
     5. High performance Computing, Grid Computing and Cloud Technologies
  4. Engineering and fabrication technologies
     1. (Opto)mechatronics
     2. Additive manufacturing/3D printing
     3. Cyberphysical systems
     4. High frequency and mixed signal technologies
     5. Imaging technologies
     6. Robotics
     7. Sensors and actuators
  5. Life science technologies
     1. Biocatalysis
     2. Biochips and biosensors
     3. Biofabrication
     4. Gene editing/ precise genetics editing
     5. Genomics/proteomics/metabolomics/glycomics/X-omics
     6. Industrial biotechnology (white)
     7. Nanomedicine
     8. Organ on a chip
     9. Stem cell technology
     10. Synthetic cell technology
  6. Quantum technologies
     1. Quantum communication
     2. Quantum computing
     3. Quantum sensors and metrology
  7. Nanotechnologies
     1. Bionanotechnology
     2. Micro and nanofluidics
     3. Nanomanufacturing
     4. Nanomaterials
     5. Nanoscale devices
     6. Semiconductor devices
  8. Photonics and light technologies
     1. Integrated photonics
     2. Photon generation technologies
     3. Photonic detection
     4. Photovoltaics
  9. Not applicable

**Appendix F: Letter of commitment template**

[Use headed paper of party]

[Name and address of the main applicants' duly authorised representative (“bestuurlijk verantwoordelijke”)]

[Date]

***LETTER OF COMMITMENT***

*for the*

***[name of] PROJECT***

Dear [main applicants’ duly authorised representative],

I, [first name and family name], in my capacity of [position in the organisation (has to be a duly authorised person)] at [name legal entity] hereby confirm that [legal entity] is committed to contribute to the [project name] project, on the condition that Stichting LSH-TKI grants the PPP Allowance as applied for by the main applicant, [first name and family name], [position] at [name organisation].

[Name legal entity] will contribute € [•] in cash towards the project costs in accordance with the budget in the project proposal and budget form.

[Name legal entity] will provide an in kind contribution of [description of the contribution], representing a monetary value of € [•] and further detailed in the project proposal and budget form.

Yours sincerely,

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name:

Position:

Date:

**Appendix G: Checklist application form**

It is the first time that the parties are jointly realising an R&D project

After the end of the project, the parties have the intention to continue the cooperation or to invest in the Netherlands

The consortium must consist of at least one research organisation and one for-profit enterprise. One of the consortium partners must be a foreign research organisation/for profit enterprise

The results of the project will benefit the Dutch knowledge infrastructure and economy

The main applicant is located in the Netherlands

The project has a duration of a maximum of 18 months

 The starting date of the project is after the date of submission to Health~Holland

The project starts within six months after the awarding letter will be received

The chamber of commerce number or equivalent is listed for all consortium partners

Effective collaboration takes place. This means, for example, that the project is realised at joint cost and risk

All consortium partners should make an *in kind* contribution. This means, for example, that all consortium partners should at least incur payroll costs

 The amount of PPP Allowance that can be applied for is between €50,000 and €120,000 per project

The PPP Allowance covers 25% (experimental development) to 50% (fundamental/industrial research) of the total eligible project costs

 Dutch SMEs and other Dutch enterprises may finance a maximum of 50% of their *in kind* costs (e.g. man hours, consumables and the use of equipment) with PPP-Allowance in the case of fundamental/industrial research and a maximum of 25% of their *in kind* costs in the case of experimental development

All parties, with the exception of the main applicant, must submit a letter of commitment; a letter of intent is not sufficient

The consortium must submit a draft consortium agreement; a blank format is not sufficient

The budgeted costs are directly related to the R&D activities, and do not include for example: bench fee costs, travel within the Netherlands, supporting/project management tasks that are not directly related to the project’s R&D activities

1. <https://wetenschapsagenda.nl/overzicht-routes/> [↑](#footnote-ref-2)
2. <https://www.hollandhightech.nl/kia-sleuteltechnologieen> [↑](#footnote-ref-3)
3. <https://www.clicknl.nl/onderzoeksagenda-kems-missiegedreven-innovatie/> [↑](#footnote-ref-4)
4. <https://www.health-holland.com/public-private-partnerships> [↑](#footnote-ref-5)
5. In case of drug development, pre-clinical research in animals falls within the research category ‘industrial research’. In principle, the clinical phases 1 and 2 fall within the research category ‘experimental development’. Phase 3 clinical trials (and beyond) are seen as competitive development and fall outside the scope of the PPP Allowance Regulation. [↑](#footnote-ref-6)